Lakewood-Amedex Biotherapeutics Inc (LABT)

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...

Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds Being Developed for High-Need Antimicrobial Infections

Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds...

Form 8-K - Current report

Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum

Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum PR Newswire SARASOTA...

Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers

Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Positive Nu-3 Data Advances Lakewood-Amedex Toward Phase 2 Diabetic Foot Ulcer Trial (LABT)

Manufacturing progress, stability data, and formulation advances are moving Lakewood-Amedex’s lead antimicrobial candidate closer to Phase 2...

Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in...